Abstract
The cAMP–protein kinase A (PKA) pathway is the major signal transduction pathway involved in melanocyte-stimulating hormone receptor-mediated signaling and melanin production, whereas its role in the control of melanocyte proliferation is still controversial. In this study, we evaluated the effects of selective activation of the different PKA regulatory subunits type 1A (R1A) and type 2B (R2B) on melanocyte proliferation. Immunohistochemistry demonstrated that normal melanocytes lacked R1A protein whereas this subunit was highly expressed in all human melanomas studied (N=20) and in six human melanoma cell lines. Pharmacological activation of the R2 subunits by the cAMP analogue 8-Cl-cAMP inhibited proliferation and increased caspase-3 activity by 68.77±10.5 and 72±9% respectively, in all cell lines with the exception of the only p53-mutated one. Similar effects were obtained by activating R2 subunits with other analogues and by silencing R1A expression. The antiproliferative and proapoptotic effects of 8-Cl-cAMP were comparable to those observed with commonly used antitumoral drugs. Moreover, 8-Cl-cAMP potentiated the effects of these drugs on both cell proliferation and caspase-3 activity. In conclusion, this study first reports that human melanomas are characterized by a high R1/R2 ratio and that pharmacological and genetic manipulations able to revert this unbalanced expression cause significant antiproliferative and proapoptotic effects in melanoma cells.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Cho YS, Park YG, Lee YN, Kim MK, Bates S, Tan L et al. (2000). Extracellular proteinkinase A as a cancer biomarker: its expression by tumor cells and reversal by a myristate-lacking Calpha and RIIbeta subunit overexpression. Proc Nat Acad Sci USA 97: 835–840.
Cho-Chung YS, Nesterova MV . (2005). Tumor reversion: protein kinase A isozyme switching. Ann NY Acad Sci 1058: 76–86.
Cho-Chung YS, Pepe S, Clair T, Budillon A, Nesterova M . (1995). cAMP-dependent protein kinase: role in normal and malignant growth. Crit Rev Oncol Hematol 21: 2133–2161.
Cho-Chung YS . (1990). Role of cyclic AMP receptor proteins in growth, differentiation, and suppression of malignancy: new approaches to therapy. Cancer Res 50: 7093–7100.
Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H et al. (2005). Distinct sets of genetic alterations in melanoma. N Engl J Med 353: 2135–2147.
Daniotti M, Oggionni M, Ranzani T, Vallacchi V, Campi V, Di Stasi D et al. (2004). BRAF alterations are associated with complex mutational profiles in malignant melanoma. Oncogene 23: 5968–5977.
Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S et al. (2002). Mutations of the BRAF gene in human cancer. Nature 417: 949–954.
De Luca M, Siegrist W, Bondanza S, Mathor M, Cancedda R, Eberle AN . (1993). Alpha melanocyte stimulating hormone (alpha MSH) stimulates normal human melanocyte growth by binding to high-affinity receptors. J Cell Sci 105: 1079–1084.
Di Stasi D, Vallacchi V, Campi V, Ranzani T, Daniotti M, Chiodini E et al. (2005). DHCR24 gene expression is upregulated in melanoma metastases and associated to resistance to oxidative stress-induced apoptosis. Int J Cancer 115: 224–230.
Dumaz N, Marais R . (2005). Integrating signals between cAMP and the RAS/RAF/MEK/ERK signalling pathways. FEBS J 272: 3491–3504.
Handschin JS, Eppenberger U . (1979). Altered cellular ratio of type I and type II cyclic AMP-dependent protein kinase in human mammary tumors. FEBS Lett 106: 301.
Hunt G, Donatien PD, Lunec J, Todd C, Kyne S, Thody AJ . (1994). Cultured human melanocytes respond to MSH peptides and ACTH. Pigment Cell Res 7: 217–221.
Kirschner LS, Carney JA, Pack SD, Taymans SE, Giatzakis C, Cho YS et al. (2000). Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex. Nat Genet 26: 89–92.
Landis CA, Masters SB, Spada A, Pace AM, Bourne HR, Vallar L . (1989). GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature 340: 692–696.
Lania A, Mantovani G, Spada A . (2001). G protein mutations in endocrine diseases. Eur J Endocrinol 145: 543–559.
Lania AG, Mantovani G, Ferrero S, Pellegrini C, Bondioni S, Peverelli E et al. (2004). Proliferation of transformed somatotroph cells related to low or absent expression of PKA regulatory subunit 1A protein. Cancer Res 64: 9193–9198.
Levine N, Sheftel SN, Eytan T, Dorr RT, Hadley ME, Weinrach JC et al. (1991). Induction of skin tanning by subcutaneous administration of a potent synthetic melanotropin. J Am Med Assoc 266: 2730–2736.
Miller AJ, Mihm Jr MC . (2006). Melanoma. N Engl J Med 355: 51–65.
Nesterova M, Yokozaki H, McDuffie E, Cho-Chung YS . (1996). Overexpression of RII beta regulatory subunit of PKA in human colon carcinoma cell induces growth arrest and phenotypic changes that are abolished by site-directed mutation of RII beta. Eur J Biochem 235: 486–494.
Rohlff C, Clair T, Cho-Chung YS . (1993). 8-Cl-cAMP induces truncation and down-regulation of the RI alpha subunit and up-regulation of the RII beta subunit of cAMP-dependent protein kinase leading to type II holoenzyme-dependent growth inhibition and differentiation of HL-60 leukemia cells. J Biol Chem 268: 5774–5782.
Schwede F, Christensen A, Liauw S, Hippe T, Kopperud R, Jastorff B et al. (2000). 8-Substituted cAMP analogues reveal marked differences in adaptability, hydrogen bonding, and charge accommodation between homologous binding sites (AI/AII and BI/BII) in cAMP kinase I and II. Biochem 39: 8803–8812.
Siddik ZH . (2003). Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22: 7265–7279.
Tanami H, Imoto I, Hirasawa A, Yuki Y, Sonoda I, Inoue J et al. (2004). Involvement of overexpressed wild-type BRAF in the growth of malignant melanoma cell lines. Oncogene 23: 8796–8804.
Tortora G, Clair T, Cho-Chung YS . (1990). An antisense oligodeoxynucleotide targeted against the type RIIh regulatory subunit mRNA of protein kinase inhibits cAMP-induced differentiation in HL-60 leukemia cells without affecting phorbol ester effects. Proc Natl Acad Sci USA 87: 705–708.
Weinstein LS, Shenker A, Gejman P, Marino MJ, Friedman E, Spiegel AM . (1991). Activating mutations of the stimulatory G protein in the McCune–Albright syndrome. N Engl J Med 325: 1688–1695.
Acknowledgements
This work was supported by AIRC (Associazione Italiana Ricerca Cancro), Milan and by Ricerca Corrente Funds of Fondazione Policlinico IRCCS, Milan. PRIN grant 2006060982-002, Rome.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mantovani, G., Bondioni, S., Lania, A. et al. High expression of PKA regulatory subunit 1A protein is related to proliferation of human melanoma cells. Oncogene 27, 1834–1843 (2008). https://doi.org/10.1038/sj.onc.1210831
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1210831
Keywords
This article is cited by
-
cAMP-PKA/EPAC signaling and cancer: the interplay in tumor microenvironment
Journal of Hematology & Oncology (2024)
-
Complex roles of cAMP–PKA–CREB signaling in cancer
Experimental Hematology & Oncology (2020)
-
The α-melanocyte stimulating hormone/peroxisome proliferator activated receptor-γ pathway down-regulates proliferation in melanoma cell lines
Journal of Experimental & Clinical Cancer Research (2017)
-
PKA-induced dimerization of the RhoGAP DLC1 promotes its inhibition of tumorigenesis and metastasis
Nature Communications (2013)
-
Cyclic AMP induces apoptosis in multiple myeloma cells and inhibits tumor development in a mouse myeloma model
BMC Cancer (2011)